Given the expression profiles of Tc from human PDAC patients, Balli et al. suggested that patients with pancreatic cancer can be categorized to apply patient-specific treatment modalities based on co-expression of CTLA-4, TIGIT, TIM-3 and VISTA (Figure 2) [132]. The gene discussed is HAVCR2; the disease is pancreatic neoplasm.